Sorriso Pharmaceuticals

Executive Summary

Sorriso Pharmaceuticals is a preclinical-stage biopharmaceutical company pioneering orally delivered single-domain antibodies for immune-mediated diseases, with an initial focus on inflammatory bowel disease (IBD). Founded in 2018 and based in Cambridge, MA, the company leverages a proprietary platform to generate potent antibody fragments (VHH) that remain stable and active in the gastrointestinal tract, overcoming the traditional challenge of oral protein delivery. By targeting both TNFα and IL-23 with a single molecule (SOR102), Sorriso aims to address the high unmet need for safe, convenient, and effective oral therapies in IBD, a market dominated by injectable biologics. Lead candidate SOR102 is currently in Phase 1 clinical development, with initial safety and pharmacokinetic data expected within the next 12-18 months. The platform's ability to combine two validated targets in one oral drug could differentiate Sorriso in a competitive landscape. While the company is private with limited public information, its innovative approach and early-stage progress warrant attention. Upcoming catalysts include Phase 1 data readout, potential IND filings for additional indications, and possible partnership or financing events as the company advances toward proof-of-concept.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 SOR102 safety and PK data readout50% success
• Q2 2027Initiation of Phase 2 trial in ulcerative colitis or Crohn's disease40% success
• Q2 2027Potential platform licensing or partnership deal30% success